Evidence map›Paper›PMID 25475176›Full record

ReviewSeminars in cell & developmental biology2015

Effects of N-glycan precursor length diversity on quality control of protein folding and on protein glycosylation.

John Samuelson, Phillips W Robbins

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in cell & developmental biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Deciphering theBiomolecules · 2025
    Review
  5. Review
  6. Molecular therapy. Oncology · 2025
    Article
  7. Evolutionary uniqueeLife · 2025
    Article
  8. Review
  9. Towards understanding the extensive diversity of protein N-glycan structures in eukaryotes.Biological reviews of the Cambridge Philosophical Society · 2022
    Review
  10. Review
  11. Compounds targeting GPI biosynthesis orComputational and structural biotechnology journal · 2022
    Article
  12. Article
  13. Pathogens (Basel, Switzerland) · 2021
    Article
  14. Article
  15. Article
  16. ProteinParasitology · 2019
    Review
  17. Article
  18. CRISPR/Cas9 and glycomics tools forThe Journal of biological chemistry · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

John SamuelsonDepartment of Molecular and Cell Biology, Boston University Goldman School of Dental Medicine, 72 East Concord St, Evans 425, Boston, MA 02118, USA. Electronic address: jsamuels@bu.edu.
Phillips W RobbinsDepartment of Molecular and Cell Biology, Boston University Goldman School of Dental Medicine, 72 East Concord St, Evans 425, Boston, MA 02118, USA. Electronic address: robbinspw2@gmail.com.
Boston University · US

Funding

ROBBINS Glycosylation and Glycosidases-Cell and Molecular BiologyR01GM031318 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SAMUELSON, JOHN C. · 1985 to 2011
$4.1M
THREE LECTIN MODEL OF AMEBIC ENCYSTATION AND EXCYSTATIONR01AI044070 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI SAMUELSON, JOHN C. · 2000 to 2010
$4.0M
Glycobiology of GiardiaR01AI048082 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SAMUELSON, JOHN C. · 2003 to 2015
$4.0M
PROTEIN GLYCOSYLATION - CELLULAR AND MOLECULAR BIOLOGYR37GM031318 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ROBBINS, PHILLIPS W · 1988 to 1997
–
NIAID NIH HHS AI048082NIAID NIH HHS AI44070NIAID NIH HHS R01 AI044070NIAID NIH HHS R01 AI048082NIGMS NIH HHS GM031318NIGMS NIH HHS R01 GM031318
6 · The paper itself

Abstract

Asparagine-linked glycans (N-glycans) of medically important protists have much to tell us about the evolution of N-glycosylation and of N-glycan-dependent quality control (N-glycan QC) of protein folding in the endoplasmic reticulum. While host N-glycans are built upon a dolichol-pyrophosphate-linked precursor with 14 sugars (Glc3Man9GlcNAc2), protist N-glycan precursors vary from Glc3Man9GlcNAc2 (Acanthamoeba) to Man9GlcNAc2 (Trypanosoma) to Glc3Man5GlcNAc2 (Toxoplasma) to Man5GlcNAc2 (Entamoeba, Trichomonas, and Eimeria) to GlcNAc2 (Plasmodium and Giardia) to zero (Theileria). As related organisms have differing N-glycan lengths (e.g. Toxoplasma, Eimeria, Plasmodium, and Theileria), the present N-glycan variation is based upon secondary loss of Alg genes, which encode enzymes that add sugars to the N-glycan precursor. An N-glycan precursor with Man5GlcNAc2 is necessary but not sufficient for N-glycan QC, which is predicted by the presence of the UDP-glucose:glucosyltransferase (UGGT) plus calreticulin and/or calnexin. As many parasites lack glucose in their N-glycan precursor, UGGT product may be identified by inhibition of glucosidase II. The presence of an armless calnexin in Toxoplasma suggests secondary loss of N-glycan QC from coccidia. Positive selection for N-glycan sites occurs in secreted proteins of organisms with N-glycan QC and is based upon an increased likelihood of threonine but not serine in the +2 position versus asparagine. In contrast, there appears to be selection against N-glycan length in Plasmodium and N-glycan site density in Toxoplasma. Finally, there is suggestive evidence for N-glycan-dependent ERAD in Trichomonas, which glycosylates and degrades the exogenous reporter mutant carboxypeptidase Y (CPY*).

Indexed as

Protein FoldingAnimalsEndoplasmic ReticulumEukaryotaGlycoproteinsGlycosylationHumansModels, BiologicalPolysaccharidesProtozoan ProteinsGlycoproteinsPolysaccharidesProtozoan ProteinsEndoplasmic reticulumER-associated degradationEvolutionN-glycan precursorsParasitesQuality control of protein folding

Identifiers

PMID25475176
PMCPMC4452448
OpenAlexW1983505511

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.